Today, in the AbbVie v. Amgen adalumimab case, the parties filed a joint proposed scheduling order.  The parties jointly proposed a bench trial commencing the week of November 4, 2019, with completion of fact discovery by January 15, 2018 and expert discovery by May 24, 2019.  AbbVie noted that the proposed schedule is for the ten patents-in-suit, and that “[w]hen Amgen provides notice of commercial marketing (which it is required to do 180 days before launch), Abbvie will bring suit on the remaining patents,” and that    “[g]iven the overlap between this lawsuit and the future suit, depending on when Amgen provides commercial marketing notice, a change in the schedule for this litigation may be warranted.”

A scheduling conference before Judge Robinson is set to occur tomorrow, November 1, 2016, at 3 p.m.

Stay tuned to the Big Molecule Watch for further updates on this litigation.